Sai Parenteral's IPO Subscribed 1.08 Times on Day 3

Sai Parenteral's Limited's initial public offering (IPO) closed its three-day subscription window at 1.08 times overall subscription by 4:49 PM on Day 3 (March 27, 2026). The ₹408.79 crore book-build issue, priced at ₹372 to ₹392 per share, received bids for 78,77,172 shares against 72,99,803 shares on offer, with total applications reaching 7,883.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Subscription Status of Sai Parenteral's IPO

Here are the subscription details for Sai Parenteral's IPO  Day 3, as of 4:49 PM:

Key Highlights – Day 3

• Overall subscription crossed full subscription at 1.08 times, surging from Day 2's 0.42 times, driven by a sharp final-day surge in institutional and NII demand.
• Non-institutional investors led at 2.45 times, improving from Day 2's 1.05 times, with bNII at 3.56 times against sNII's subdued 0.24 times.
• Qualified institutional buyers (ex-anchor) crossed full subscription at 1.73 times, surging from Day 2's 0.60 times, indicating heavy institutional interest concentrated on the closing day of this pharmaceutical formulations IPO.
• Retail investors remained subdued at 0.12 times, improving marginally from Day 2's 0.05 times.
• Total applications reached 7,883 on Day 3.

Key Highlights – Day 2

• Overall subscription reached 0.42 times, showing substantial improvement from Day 1's 0.05 times, driven by strong institutional and HNI demand.
• Non-institutional investors crossed full subscription at 1.05 times, surging from Day 1's 0.15 times, with bNII at 1.55 times against sNII's subdued 0.04 times.
• Qualified institutional buyers (ex-anchor) improved to 0.60 times from no participation on Day 1, indicating growing institutional interest heading into the final day.
• Retail investors remained negligible at 0.05 times on Day 2.

Key Highlights - Day 1

• Overall subscription reached 0.05 times, reflecting subdued initial investor interest in this pharmaceutical formulations IPO.
• Non-institutional investors showed the strongest opening participation at 0.15 times, with bNII at 0.22 times and sNII at 0.03 times on Day 1.
• Retail investors showed negligible participation at 0.03 times on Day 1.
• Qualified institutional buyers (ex-anchor) showed no participation on Day 1.
• Anchor investors fully subscribed their allocation of ₹122.64 crores on March 23, 2026.

About Sai Parenteral's Limited

Incorporated in 2001, Sai Parenteral's Limited is a diversified pharmaceutical formulations company engaged in branded generic formulations and contract development and manufacturing (CDMO) for domestic and international markets. The company operates five manufacturing facilities, four in Hyderabad, Telangana, and one through its subsidiary Revat Laboratories in Ongole, Andhra Pradesh, and exports to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa. As of December 31, 2025, the company employed 298 full-time employees.